353 related articles for article (PubMed ID: 24053564)
1. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
Krege S; Rexer H; vom Dorp F; de Geeter P; Klotz T; Retz M; Heidenreich A; Kühn M; Kamradt J; Feyerabend S; Wülfing C; Zastrow S; Albers P; Hakenberg O; Roigas J; Fenner M; Heinzer H; Schrader M
BJU Int; 2014 Mar; 113(3):429-36. PubMed ID: 24053564
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
3. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
5. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Paz-Ares LG; Biesma B; Heigener D; von Pawel J; Eisen T; Bennouna J; Zhang L; Liao M; Sun Y; Gans S; Syrigos K; Le Marie E; Gottfried M; Vansteenkiste J; Alberola V; Strauss UP; Montegriffo E; Ong TJ; Santoro A;
J Clin Oncol; 2012 Sep; 30(25):3084-92. PubMed ID: 22851564
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
7. [Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Wang Y; Wang L; Liu Y; Yu S; Zhang X; Shi Y; Sun Y
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):239-44. PubMed ID: 21426666
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
Trials; 2013 Jul; 14():228. PubMed ID: 23876062
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Srimuninnimit V; Sriuranpong V; Suwanvecho S
Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Necchi A; Lo Vullo S; Raggi D; Perrone F; Giannatempo P; Calareso G; Togliardi E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Colecchia M; Busico A; Pennati M; Zaffaroni N; Mariani L; Salvioni R
Urol Oncol; 2018 Jan; 36(1):8.e1-8.e8. PubMed ID: 28911922
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Hurwitz ME; Markowski P; Yao X; Deshpande H; Patel J; Mortazavi A; Donadio A; Stein MN; Kelly WK; Petrylak DP; Mehnert JM
Clin Genitourin Cancer; 2018 Dec; 16(6):437-444.e6. PubMed ID: 30177237
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
14. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
[TBL] [Abstract][Full Text] [Related]
15. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
20. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
